[Biosensors and Bioelectronics] A microfluidic platform for drug screening in a 3D cancer microenvir
Development of resistance to chemotherapy treatments is a major challenge in the battle against cancer. Although a vast repertoire of chemotherapeutics is currently available for treating cancer, a technique for rapidly identifying the right drug based on the chemo-resistivity of the cancer cells is not available and it currently takes weeks to months to evaluate the response of cancer patients to a drug. A sensitive, low-cost diagnostic assay capable of rapidly evaluating the effect of a series of drugs on cancer cells can significantly change the paradigm in cancer treatment management. Integration of microfluidics and electrical sensing modality in a 3D tumour microenvironment may provide a powerful platform to tackle this issue. Here, we report a 3D microfluidic platform that could be potentially used for a real-time deterministic analysis of the success rate of a chemotherapeutic drug in less than 12 h. The platform (66 mm × 50 mm; L×W) is integrated with the microsensors (interdigitated gold electrodes with width and spacing 10 µm) that can measure the change in the electrical response of cancer cells seeded in a 3D extra cellular matrix when a chemotherapeutic drug is flown next to the matrix. B16-F10 mouse melanoma, 4T1 mouse breast cancer, and DU 145 human prostate cancer cells were used as clinical models. The change in impedance magnitude on flowing chemotherapeutics drugs measured at 12 h for drug-susceptible and drug tolerant breast cancer cells compared to control were 50552 ± 144 Ω and 28786 ± 233 Ω, respectively, while that of drug-susceptible melanoma cells were 40197 ± 222 Ω and 4069 ± 79 Ω, respectively. In case of prostate cancer the impedance change between susceptible and resistant cells were 8971 ± 1515 Ω and 3281 ± 429 Ω, respectively, which demonstrated that the microfluidic platform was capable of delineating drug susceptible cells, drug tolerant, and drug resistant cells in less than 12 h.
Hardik J. Pandya a, 1, Karan Dhingra a, Devbalaji Prabhakar a, 2, Vineethkrishna Chandrasekar a, 2, Siva Kumar Natarajan a, 2, Anish S. Vasan a, Ashish Kulkarni a, Hadi Shafiee a, b, , a Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital – Harvard Medical School, Boston, MA, 02115, USA b Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA Received 22 December 2016, Revised 14 March 2017, Accepted 24 March 2017, Available online 27 March 2017 http://dx.doi.org/10.1016/j.bios.2017.03.054